YURAK-QON TOMIR KASALLIKLARIDA ANTIKOAGULYANT PREPARATLARNING SAMARADORLIGI VA GEMORRAGIK ASORATLAR XAVFI

Authors

  • Dilorom Orifjonovna Raximova Toshkent farmatsevtika instituti, farmakognoziya va dori vositalarini standartlash kafedrasi dotsenti https://orcid.org/0009-0009-9767-0898
  • Ibrahim Xudoyberdiyevich Rustamov Toshkent farmatsevtika instituti, farmakognoziya va dori vositalarini standartlash kafedrasi katta o‘qituvchisi
  • Shavkat Ubaydullayevich Nurmatov Toshkent farmatsevtika instituti, farmakognoziya va dori vositalarini standartlash kafedrasi assistenti

DOI:

https://doi.org/10.5281/zenodo.23553478

Keywords:

anticoagulants, warfarin, apixaban, rivaroxaban, atrial fibrillation, bleeding, HAS-BLED, thromboembolism

Abstract

This narrative review evaluates the efficacy of anticoagulant therapy and the risk of hemorrhagic complications in cardiovascular diseases based on Uzbekistan’s national clinical protocols and international evidence. Stroke prevention in atrial fibrillation, anticoagulant selection in patients with mechanical heart valves, and the benefits and limitations of direct oral anticoagulants (DOACs) compared with vitamin K antagonists are examined. The importance of the HAS-BLED score, renal function, concomitant medications, and treatment adherence in bleeding risk assessment is highlighted. The study is based on a descriptive review of the literature and clinical recommendations; no original clinical observations or patient data were collected.

References

1. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2025). Bo‘lmachalar fibrillyatsiyasi nozologiyasini tashxislash va davolash bo‘yicha milliy klinik protokollar. Toshkent. https://api-portal.gov.uz/uploads/10/2026/03/10/745f5b8a-36f2-1f13-0a9d-fc0316a5eea7_media_.pdf

2. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2024). Bo‘lmachalar fibrillyatsiyasi nozologiyasi bo‘yicha tibbiy aralashuvlar milliy klinik protokoli. Toshkent. https://api-portal.gov.uz/uploads/675ec2d0-9e25-7704-51c1-8b2fdb4338a4_media_.pdf

3. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2014). Yurak-qon tomir kasalliklari bo‘yicha klinik protokollar to‘plami. MED.UZ. https://med.uz/spid/uz/inuz/detail.php?IBTYPE=public&IB_ID=94&ID=50885

4. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2024). Mitral regurgitatsiya bo‘yicha milliy klinik protokol. https:// api-portal.gov.uz/uploads/8047aef0-4ef9-311f-4b70-a377bb69e8fc_media_.pdf

5. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2024). Surunkali yurak ishemik kasalligi bilan kasallangan bemorlarni davolash bo‘yicha milliy klinik protokol. https://api-portal.gov.uz/uploads/cb44a91d-d659-2595-86b3-79d93593a747_media_7631.pdf

6. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2025). Klinik protokollar va standartlar: klinik qo‘llanmalar. https:// gov.uz/oz/ssv/pages/klinik-qo-llanmalar

7. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2024, 2-iyul). Milliy klinik protokollarni yangilash jarayoni haqida.

8. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2026, 13-yanvar). “Infarkt va insultga qarshi kurashish” milliy dasturi loyihasi muhokama qilindi. https://gov.uz/oz/ssv/news/view/128884

9. Van Gelder, I. C., et al. (2024). 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 45(36), 3314–3414. https://doi.org/10.1093/eurheartj/ehae176

10. Joglar, J. A., et al. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation, 149, e1–e156. https://doi.org/10.1161/CIR.0000000000001193

Downloads

Published

2026-10-20

How to Cite

1.
Raximova DO, Rustamov IX, Nurmatov SU. YURAK-QON TOMIR KASALLIKLARIDA ANTIKOAGULYANT PREPARATLARNING SAMARADORLIGI VA GEMORRAGIK ASORATLAR XAVFI. TTI [Internet]. 2026 Oct. 20 [cited 2026 Oct. 22];2(10):415-8. Available from: https://tibbiyot-talimi-va-innovatsiyalari.uz/index.php/TTI/article/view/184
Vol. 2 No. 10 (2026): Journal of "Medical Education and Innovations"